Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) EBIT Margin (2020 - 2023)

Pliant Therapeutics has reported EBIT Margin over the past 4 years, most recently at 19083.87% for Q2 2023.

  • Quarterly EBIT Margin fell 1848972.0% to 19083.87% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 78404.03% through Mar 2024, down 7695968.0% year-over-year, with the annual reading at 11654.75% for FY2023, 1034138.0% down from the prior year.
  • EBIT Margin was 19083.87% for Q2 2023 at Pliant Therapeutics, down from 3160.29% in the prior quarter.
  • Over five years, EBIT Margin peaked at 38.04% in Q1 2020 and troughed at 19083.87% in Q2 2023.
  • The 4-year median for EBIT Margin is 1255.42% (2021), against an average of 2543.61%.
  • Year-over-year, EBIT Margin soared 68612bps in 2022 and then plummeted -1848972bps in 2023.
  • A 4-year view of EBIT Margin shows it stood at 425.89% in 2020, then crashed by -189bps to 1230.57% in 2021, then tumbled by -55bps to 1903.31% in 2022, then crashed by -903bps to 19083.87% in 2023.
  • Per Business Quant, the three most recent readings for PLRX's EBIT Margin are 19083.87% (Q2 2023), 3160.29% (Q1 2023), and 1903.31% (Q4 2022).